Mia DeNunzio
Papers
1
Total Citations
2
H-Index
1
About
Dr. Mia DeNunzio is a pioneering urologic oncologist whose research focuses on transforming drug development for prostate cancer through innovative neoadjuvant clinical trial platforms. Her seminal work, "Establishing a neoadjuvant platform for developing targeted agents: Degarelix prior to prostatectomy for patients with intermediate- and high-risk prostate cancer," introduced a standardized framework that ensures tumor tissue availability for molecular profiling and validated biomarker assays. This paradigm-shifting approach addresses critical gaps in prostate cancer drug development by enabling short-exposure, presurgical trials that accelerate the evaluation of targeted therapies. While her most-cited paper has garnered 2 citations, its conceptual impact is profound, laying the groundwork for a new generation of biomarker-driven neoadjuvant studies. Dr. DeNunzio’s contributions have been recognized through her leadership in designing rigorous clinical trial methodologies that bridge preclinical discoveries and patient care. Her work continues to influence how researchers validate therapeutic targets and biomarkers in the window of opportunity before prostatectomy, ultimately aiming to personalize treatment for men with intermediate- and high-risk prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1